Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H17F2N3O2 |
| Molecular Weight | 345.3433 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCOC1=C2C=NNC2=NC=C1C(=O)C3=C(F)C=C(C)C=C3F
InChI
InChIKey=SCFMWQIQBVZOQR-UHFFFAOYSA-N
InChI=1S/C18H17F2N3O2/c1-3-4-5-25-17-11(8-21-18-12(17)9-22-23-18)16(24)15-13(19)6-10(2)7-14(15)20/h6-9H,3-5H2,1-2H3,(H,21,22,23)
| Molecular Formula | C18H17F2N3O2 |
| Molecular Weight | 345.3433 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/12824044Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21216932
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12824044
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21216932
BMS 265246 is a potent inhibitor of cyclin dependent kinase 1 and 2. It was under investigation with BristolMyers Squibb in the USA with potential in the treatment of cancer, however, BristolMyers Squibb no longer lists this product on its research and development pipelines which suggests that development of the programme has been discontinued.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1907602 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12824044 |
0.006 µM [IC50] | ||
Target ID: CHEMBL2094126 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12824044 |
0.009 µM [IC50] | ||
Target ID: CHEMBL2095942 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12824044 |
0.23 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12824044
Kinase reactions consisted of 100 ng of baculovirus expressed GST-CDK1/cyclin B1 complex, 1 µg histone H1 (Boehringer Mannheim, Indianapolis, IN), 0.2 µCi 33P γ-ATP, 25 µM ATP in 50 µL of kinase buffer (50 mM Tris, pH 8.0, 10 mM MgCl2, 1 mM EGTA, 0.5 mM DTT). Reactions were incubated for 45 min at 30 °C and stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration of 15%. TCA precipitates were collected onto GF/C unifilter plates (Packard Instrument Co., Meriden, CT) using a Filtermate universal harvester (Packard Instrument Co.), and the filters were quantitated using a TopCount 96 well liquid scintillation counter (Packard Instrument Co.). Dose response curves were generated to determine the concentration required to inhibit 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in DMSO and evaluated at six concentrations, each in triplicate. The final concentration of DMSO in the assay equaled 2%.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:40:51 GMT 2025
by
admin
on
Mon Mar 31 22:40:51 GMT 2025
|
| Record UNII |
4GF4A623RF
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID00206969
Created by
admin on Mon Mar 31 22:40:51 GMT 2025 , Edited by admin on Mon Mar 31 22:40:51 GMT 2025
|
PRIMARY | |||
|
582315-72-8
Created by
admin on Mon Mar 31 22:40:51 GMT 2025 , Edited by admin on Mon Mar 31 22:40:51 GMT 2025
|
PRIMARY | |||
|
4GF4A623RF
Created by
admin on Mon Mar 31 22:40:51 GMT 2025 , Edited by admin on Mon Mar 31 22:40:51 GMT 2025
|
PRIMARY | |||
|
5329775
Created by
admin on Mon Mar 31 22:40:51 GMT 2025 , Edited by admin on Mon Mar 31 22:40:51 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |